mdl 100240 has been researched along with Cirrhosis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Belloni, AS; Guidolin, D; Nussdorfer, GG; Pessina, AC; Rossi, GP; Seccia, TM; Sticchi, D | 1 |
1 other study(ies) available for mdl 100240 and Cirrhosis
Article | Year |
---|---|
The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Atrial Natriuretic Factor; Benzazepines; Creatinine; Fibrosis; Hypertension; Kidney; Male; Neprilysin; Pyridines; Ramipril; Rats; Receptor, Bradykinin B2 | 2006 |